000			01868 a2200505 4500
005			20250516024604.0
264		0	_c20110512
008			201105s 0 0 eng d
022			_a1549-490X
024	7		_a10.1634/theoncologist.2011-S2-14 _2doi
040			_aNLM _beng _cNLM
100	1		_aHutson, Thomas E
245	0	0	_aTargeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. _h[electronic resource]
260			_bThe oncologist _c2011
300			_a14-22 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
650	0	4	_aAngiogenesis Inhibitors _xtherapeutic use
650	0	4	_aAntibodies, Monoclonal _xtherapeutic use
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aBenzenesulfonates _xtherapeutic use
650	0	4	_aBevacizumab
650	0	4	_aCarcinoma, Renal Cell _xdrug therapy
650	0	4	_aClinical Trials as Topic
650	0	4	_aCombined Modality Therapy
650	0	4	_aDisease-Free Survival
650	0	4	_aEverolimus
650	0	4	_aHumans
650	0	4	_aImmunotherapy _xmethods
650	0	4	_aIndoles _xtherapeutic use
650	0	4	_aInterferon-alpha _xtherapeutic use
650	0	4	_aInterleukin-2 _xtherapeutic use
650	0	4	_aKidney Neoplasms _xdrug therapy
650	0	4	_aMolecular Targeted Therapy _xmethods
650	0	4	_aNiacinamide _xanalogs & derivatives
650	0	4	_aPhenylurea Compounds
650	0	4	_aPyridines _xtherapeutic use
650	0	4	_aPyrroles _xtherapeutic use
650	0	4	_aSirolimus _xanalogs & derivatives
650	0	4	_aSorafenib
650	0	4	_aSunitinib
650	0	4	_aTreatment Outcome
773	0		_tThe oncologist _gvol. 16 Suppl 2 _gp. 14-22
856	4	0	_uhttps://doi.org/10.1634/theoncologist.2011-S2-14 _zAvailable from publisher's website
999			_c20621858 _d20621858